CTOs on the Move

Pernix Therapeutics Holdings, Inc.

www.pernixtx.com

 
Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: TREXIMET®, SILENOR®, a non-narcotic product indicated for the treatment of insomnia characterized by difficulties with sleep maintenance, KHEDEZLA™, as well as CEDAX®, an antibiotic for middle ear infections. The Company promotes its branded products to physicians through its Pernix sales force and distributes its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is based in Morristown, New Jersey.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.pernixtx.com
  • 10 N Park Pl Ste 201
    Morristown, NJ USA 07960
  • Phone: 800.793.2145

Executives

Name Title Contact Details

Similar Companies

Cetylite Industries Inc

Cetylite Industries Inc is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Serán Bioscience,

Serán Bioscience is a contract development and manufacturing organization (CDMO) that provides drug development services to the pharmaceutical industry, including chemistry, formulation, spray drying, dosage form, analytical, and GMP manufacturing serv...

CAREstream America

Specializing in Respiratory, Patient Monitoring, Diagnostic, Anesthesia, Ventilation Biomedical and Plastic Surgery Products.

Bactolac Pharmaceutical Inc

We are completely committed to the success of every one of our client-partners and dedicate ourselves to quality and efficiency. We provide custom formulation and quality manufacturing for your existing formulas and welcome the opportunity to provide

Astellas Pharma

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate.